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Abstract: Uterine myomas represent one of the most frequently manifested benign tumors in women. They
originate from smooth muscle cells of myometrium or its blood vessels. Many studies suggest that inflammation
and pro-inflammatory factors may play a role in the carcinogenesis with an involvement of the transcription
factor NF-kB which activity can be controlled by various environmental factors, including many cytokines. The
aim of the study was to investigate the expression of NF-B, interleukin-1b (IL-1b), tumor necrosis factor
a (TNF-a), cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) in myometrium and uterine
myomas of women of various age. The expression of NF-kB, selected cytokines and enzymes was estimated in
women of reproductive or perimenopausal age by semiquantitative immunohistochemistry. The expression of
the examined proteins was higher in myomas than in control myometrium and was dependent on the size of
myomas and the age of women. However, the expression of the cytoplasmic NF-kB observed in uterine myomas
was independent on the size of myomas and no significant differences were observed in the number of stained
nuclei between control and myoma groups. Thus, the expression of proinflammatory factors in myomas was not
accompanied by the nuclear activation of NF-kB p65. The results of our study indicate that the examined factors
may be involved in the pathogenesis of benign tumors and not only malignant diseases. (Folia Histochemica et
Cytobiologica 2013, Vol. 51, No. 1, 73–83)
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Introduction
Uterine myomas are the most common benign tumors
in women, but in spite of this, the mechanisms and
factors that control their formation and development
are poorly understood. Many studies showed the par-
ticipation of pro-inflammatory factors in the patho-
genesis of various types of cancer [1–4] through their
effects on cell growth and differentiation, apoptosis,
angiogenesis, and tissue remodeling [1, 2, 4, 5], i.e.
events that are central to tumor growth.
Nuclear factor kB (NF-kB) represents an impor-
tant transcription factor which participates in several
cellular reactions to environmental changes. The ac-
tivity of NF-kB is an important element in the specif-
ic and non-specific mechanism of immune control
over inflammatory processes and is tightly controlled
by several regulatory proteins (e.g. tumor necrosis
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factor a [TNF-a] or interleukin-1). The genes regu-
lated by NF-kB involve those coding for cytokines,
including interleukin-1b (IL-1b), interleukin-6 (IL-6)
or TNF-a, and genes coding for anti-apoptotic pro-
teins or proteins which control cell proliferation [4,
6–8]. They also include genes coding for cyclooxyge-
nase 2 (COX-2) and inducible nitric oxide synthase
(iNOS) [9–12]. Cyclooxygenases form a group of en-
zymes involved in many inflammatory processes. Two
forms of the enzyme include the constitutive form,
COX-1 and the inducible form, COX-2. Normal uter-
ine smooth muscle cells contain both forms of the
enzyme. COX-2, which converts arachidonic acid into
prostaglandin H2 (precursor of all prostaglandins
[PGs] and thromboxanes), represents a mitogen-in-
duced form of cyclooxygenase, manifesting expres-
sion in response to various inflammatory stimuli in-
cluding IL-1b and TNF-a. In myometrium and en-
dometrium estrogens stimulate COX-2 to synthesize
PGE2 [13]. The PGE2 is associated with proinflamma-
tory mechanisms and could enhance the function of
NFkB, whereas the PGA1, PGA2 and PGJ2 are associ-
ated with suppression of inflammation and are able to
inhibit NF-kB activation [14–16]. Inducible NOS was
identified in several cell types, including macrophages
and smooth muscle cells [17]. Nitric oxide, synthesized
by iNOS, is a mediator involved in various cellular pro-
cesses. Expression of iNOS was found also in tumors
of female reproductive tract [18–20].
IL-1b and TNF-a stimulate TRAF6 (tumor ne-
crosis factor receptor associated factor 6) [21], the
effect of which directly stimulates the expression of
NF-kB [22]. IL-1b and TNF-a increase the level of
iNOS mRNA by transcriptional activation [23]. These
cytokines also increase the expression of COX-2, the
activity of which is controlled by NOS, particularly by
its inducible form [24]. Moreover, high level of estro-
gens activates iNOS [25, 26], which may significantly
affect physiology of myometrium. An increased re-
lease of estrogens as a result of induction of aromatase
[27] results in increased risk of myoma development
due to a direct stimulation of proliferation [28] and
increased activity of cyclooxygenase-2 [29].
To our knowledge, the localization and cellular
expression of NF-kB and iNOS in uterine myomas has
not yet been examined, thus the aim of the presented
study was to investigate by immunocytochemistry the
expression of NF-kB, IL-1b, TNF-a, COX-2, iNOS
in uterine myomas in women of reproductive or peri-
menopausal age.
Material and methods
Human material. Recruitment of patients, clinical studies
and hormonal tests were conducted in the Chair and De-
partment of Gynecological Endocrinology, Medical Univer-
sity of Silesia in Katowice, Poland, while enzymatic and pro-
tein studies were executed in the Department of Proteomics.
The studies were conducted on 40 patients with myo-
mas at the reproductive age (below 45th year of age, FSH
< 30 mIU/mL; samples collected during the follicular phase
of menstrual cycle) and 40 patients with myomas at the per-
imenopausal age (45–55 years, FSH >30 mIU/mL). Inclu-
sion criteria involved myoma detected by USG, qualifica-
tion of the patient to hysterectomy, informed consent to
the planned studies. The exclusion criteria included: thera-
py with any drugs, including hormonal drugs for at least
3 months before inclusion to the studies, neoplastic disease,
endometrial hypertrophy, metabolic and systemic distur-
bances, and nicotinism. In these studies we used only mate-
rial from uteruses with one large myoma or one large and
few small myomas.
Myometrial samples (control groups) were taken from
10 women (< 40 years old) undergoing hysterectomies for
ovary tumors and 10 older women (> 52 years old) under-
going hysterectomies for uterine prolapse.
The investigative procedures were approved by the lo-
cal Medical Bioethical Commission.
Characteristics of studied groups. Group 1 denoted as “con-
trol group of reproductive age women”: myometrium of
young women, in whom hysterectomy was performed for
reasons other than uterine leiomyomas (n = 10). Group 2
denoted as ”small myomas of reproductive age women”:
leiomyomas of < 3 cm in diameter (n = 20). Group 3 de-
noted as ”large myomas of reproductive age women”: lei-
omyomas of > 5 cm in diameter (n = 20). Group 4 denoted
as “control group of perimenopausal age women: myometri-
um of perimenopausal age women, in whom hysterectomy
was performed for reasons different than uterine leiomyo-
mas (n = 10). Group 5 denoted as ”small myomas of peri-
menopausal age women”: leiomyomas of < 3 cm in diame-
ter (n = 20). Group 6 denoted as ”large myomas of peri-
menopausal age women”: leiomyomas of > 5 cm in diame-
ter (n = 20).
Immunohistochemical studies. Tissue samples were fixed
in 10% (v/v) solution of buffered formalin for 24 h at 4°C,
and then dehydrated, cleared in xylenes and embedded in
paraffin. Paraffin sections (5 mm) were mounted on silane-
coated slides, de-waxed, and rehydrated. The sections were
treated with 10 mM citrate buffer, pH 6.0 in water bath
(30 min at 95°C) for antigen retrieval, then treated with 1.5%
(v/v) H2O2 in methanol for 10 min for quenching of endog-
enous peroxidase activity, and equilibrated in 10 mM PBS-
0.05% v/v Tween 20 pH 7.5. Nonspecific binding was re-
duced by incubation in 1% BSA for 60 min. After this the
slides were incubated with rabbit anti-NF-kB p65 (sc-109,
Santa Cruz Biotech, Santa Cruz, CA USA), anti-IL-1b
(ab2105, Abcam, Cambridge, MA, USA), anti-iNOS
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(ab15323, Abcam) and anti-TNF-a (ab6671, Abcam) poly-
clonal antibodies or mouse anti-COX-2 monoclonal anti-
body (sc-58344, Santa Cruz) in a humidified chamber for
22 h at 4°C. After washing in PBS-Tween 20 the sections
were incubated with biotinylated goat anti-rabbit or horse
anti-mouse immunoglobulins (Vector Laboratories, Burl-
ingame, VA, USA) for 30 min, and next with avidin-bioti-
nylated peroxidase complex (Vector) for 30 min. The bound
antibodies were visualised with diaminobenzidine (DAB)
and H2O2 in PBS, pH 7.5 according to supplier’s instruc-
tions (Vector). Finally, the tissues were stained with Gill’s
hematoxilin, dehydrated, and cover-slipped. Negative con-
trols were performed by substituting the primary antibod-
ies with rabbit IgG or mouse IgG respectively.
Archives. Photographic documentation was prepared using
a light photomicroscope. In order to accentuate the immune
reactions, every reaction was documented by 10 photographs
under 200 × magnification (20 × objective and 10 × ocular)
using a digital camera-equipped Nikon microscope.
Optical density measurements. In each positively stained
cell, the intensity of staining was measured as the optical
density of the reaction product, with the program KS 300
VIDAS video image analyzer served by IBAS 2.5 system
and a digital camera. For each analyzed area, 173 × 130 mm
average optical density was calculated [30]. Three sections
for every studied protein and every patient were analyzed.
In each section ten fields were examined. Finally, the arith-
metic mean and standard deviation were calculated.
Statistical analysis. Normal distribution of the data was
confirmed by the Kolmogorov-Smirnov test. Results are
presented as a mean ± standard deviation. The Student’s
t-test was performed. A P value < 0.05 was considered to
be statistically significant.
Results
Expression of the nuclear transcription factor kB
(NF-kB)
NF-kB showed both nuclear and cytoplasmic stain-
ing. No significant differences were observed in the
number of stained nuclei between control groups and
myoma groups (small and large myomas) in women
of different age (data not shown).
Cytoplasmic localization and its analysis
Reproductive age. Cytoplasmic expression of NF-kB
was about 100% higher in small and large myomas of
reproductive age women than in the control (Table 1,
Figure 1).
Perimenopausal age. Cytoplasmic NF-kB expres-
sion in small myomas was increased to almost 150%
of the control level, and in large myomas to 140% of
the control level (Table 1, Figure 1).
Effect of age. Cytoplasmic NF-kB expression was
similar in both control groups (Table 1). In perimeno-
pausal age women the expression of NF-kB was low-
er in both studied myoma groups as compared to my-
omas of young women.
Interleukin-1b (IL-1b)
Reproductive age
Expression of IL-1b in young women with small my-
omas was clearly higher than in the control and
reached 550% of the control level (Table 1, Figure 2).
IL-1b expression in large myomas amounted to
635% of the control level. Expression of the interleu-
Table 1. Quantitative evaluation of protein expression by immunohistochemical staining in myometrium and myomas
of reproductive and perimenopausal age women
Protein Reproductive age Perimenopausal age
Control group Small myomas Large myomas Control group Small myomas Large myomas
NF-kB 57.1 ± 10.7 120.6 ± 13.9 a 119.5 ± 8.8 b 59.0 ± 9.0 87.0 ± 10.2 a.e 82.0 ± 11.3 b.f
IL-1 33.2 ± 3.9 183.4 ± 9.1a 210.6 ± 12.2b.c 38.4 ± 4.7 195.3 ± 12.4a 175.1 ± 11.1b.d.f
TNF-a 67.3 ± 7.9 121.5 ± 8.3 a 133.3 ± 10.2 b 72.2 ± 7.0 140.9 ± 9.0 a.e 110.2  ±  8.9 b.d.f
COX-2 51.8 ± 11.7 110.4 ± 13.1 a 116.5 ± 11.5 b 56.9 ± 9.5 122.9 ± 14.1 a 85.5  ± 10.5 b.d.f
iNOS 63.4 ± 9.4 115.7 ± 6.2 a 135.3 ± 8.0 b.c 67.7 ± 10.6 130.7 ± 9.2 a.e 124.6  ± 6.3 b
The staining intensity was measured as described in methods. Data show an average optical density ± SD (see material and methods). Statistical
significance was defined as a p < 0.05. asmall myomas vs. healthy myometrium; blarge myomas v. healthy myometrium; csmall v. large myomas in
reproductive age women; dsmall v. large myomas in perimenopausal age women; esmall myomas in reproductive age women v. small myomas in
perimenopausal age women; flarge myomas in reproductive age women v. large myomas in perimenopausal age women
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kin in large myomas in women of reproductive age
was higher than in small myomas.
Perimenopausal age
In women of perimenopausal age IL-1b expression
in small myomas increased to 510%, and in large
myomas to 455% of the control level (Table 1, Fig-
ure 2). In large myomas expression of IL-1b was low-
er than that in small myomas.
Effect of age
Comparison of IL-1b expression in control groups
demonstrated that it was comparable in young and
perimenopausal women (Table 1, Figure 2). Similar-
ly, comparison of small myomas in women of the two
studied age groups revealed no differences. In large
myomas the expression of IL-1b at the perimenopaus-
al age was lower and amounted to 80% of the expres-
sion seen in young women.
Tumor necrosis factor-a (TNF-a)
Reproductive age
In young women the expression of TNF-a in small
myomas was higher than in control myometrium and
amounted to about 180%. TNF-a expression in large
myomas reached 200% of the control level (Table 1,
Figure 3).
Figure 1. NF-kB presence in uteri from reproductive (A–C) and perimenopausal age women (D–F). A and D — myome-
trium of control groups, B and E — small myomas, C and F — large myomas. NF-kB was detected by IHC as described in
Methods. Total magnification 200 ×
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Perimenopausal age
The expression of TNF-a increased in women of peri-
menopausal age, in small myomas, reaching the level cor-
responding to 195% of the control value (Table 1, Fig-
ure 3). The expression of TNF-a in large myomas was
higher than in the control, reaching 155%.In uterine
myomas of women at perimenopausal age the expres-
sion of the cytokine was slightly lower in large than in
small myomas, reaching 80% of the level in the latter.
Effect of age
The expression of TNF-a was found to be similar in
young women and in women at perimenopausal age
(Table 1, Figure 3). In small myomas, in young wom-
en the expression of TNF-a reached 90% of the val-
ue disclosed in the older women. The expression of
TNF-a in large myomas of women at perimenopaus-
al age was noted to be lower, amounting to 75% of
the value detected in young women.
Cyclooxygenase-2 (COX-2)
Reproductive age
COX-2 expression in small myomas of young women
was increased to 215% of the control value (Table 1,
Figure 4), and in large myomas to 225% of the con-
trol value. In large myomas COX-2 expression was
similar to the one found in small myomas.
Figure 2. IL-1b presence in uteri from reproductive (A–C) and perimenopausal age women (D–F). A and D — myome-
trium of control groups, B and E — small myomas, C and F — large myomas. IL-1b was detected by IHC as described in
Methods. 200 ×
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Perimenopausal age
COX-2 expression increased in small myomas to the
level of almost 215% of the control value (Table 1,
Figure 4). In large myomas the expression of COX-2
was higher than in the control, reaching 150% of the
control value.
Effect of age
Expression of the enzyme in control samples was sim-
ilar in both studied age groups (Table 1, Figure 4). A
similar situation was detected upon quantitative eval-
uation of the enzyme expression in small myomas in
women of the two age groups. In large myomas the
level of COX-2 expression in women of perimeno-
pausal age was lower and corresponded to 65% of
the level detected in the younger women.
Inducible nitric oxide synthase (iNOS)
Reproductive age. In young women iNOS expression
increased in both small and large uterine myomas,
reaching 185% and 215% of the control level, respec-
tively (Table 1, Figure 5). In large myomas the ex-
pression of iNOS was higher than in small myomas
and it reached almost 120% of the enzyme expres-
sion detected in small myomas.
Figure 3. TNF-a presence in uteri from reproductive (A–C) and perimenopausal age women (D–F). A and D — myome-
trium of control groups, B and E — small myomas, C and F — large myomas. TNF-a was detected by IHC as described in
Methods. 200 ×
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Perimenopausal age
iNOS expression in perimenopausal women increased
in small myomas to the level corresponding to 190%
of the control level (Table 1, Figure 5). In large myo-
mas, as compared to the control, the expression was
higher, amounting to 185% of the control.
Effect of age
iNOS expression in young and older women was sim-
ilar (Table 1, Figure 5). In small myomas of women
at perimenopausal age the expression of iNOS was
higher (12%) than in small myomas of young wom-
en. iNOS expression in large myomas of perimeno-
pausal women was the same as that in young women.
Discussion
Pro-inflammatory factors and their regulators are
multifunctional agents and it has been shown that they
can control various processes associated with tumor-
igenesis [1–4]. IL-1b mRNA expression was identi-
fied for example in cells of melanoma, colon adeno-
carcinoma or non-small-cell lung cancer. It was found
that this pluripotent cytokine promotes angiogene-
sis, tumor growth and metastasis [2]. Our studies re-
vealed the expression of IL-1b in myometrium and
uterine myomas of women of various age, whereas
several times higher expression was observed in myo-
mas.  IL-1 may affect the growth of myomas cells, as
Figure 4. COX-2 presence in uteri from reproductive (A–C) and perimenopausal age women (D–F). A and D — myome-
trium of control groups, B and E — small myomas, C and F — large myomas. COX-2 was detected by IHC as described in
Methods. 200 ×
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it was demonstrated in the case of vascular smooth
muscle cells [31] or airway smooth muscle cells [32].
TNF-a is another cytokine with dual role in cancer
biology. This multifunctional cytokine plays a key role
in apoptosis and cell survival as well as inflammation
and immunity [33]. It can destroy blood vessels, but
also induce several angiogenic factors [1]. TNF-a is
mainly produced by activated macrophages, T lym-
phocytes, and natural killer cells, but lower expres-
sion was also observed in other cell types, including
fibroblasts, smooth muscle cells, and tumor cells.
TNF-a mRNA and protein were detected in malig-
nant and/or stromal cells in human ovarian, breast,
prostate, bladder and colorectal cancer, lymphomas
and leukemia’s, often in association with IL-1 [1, 33].
In our investigations immunoreactivity of TNF-a was
significantly higher in myoma cells than in cells of
control myometrium. These results are consistent with
studies of Kurachi et al. [34] who showed that the ex-
pression of TNF-a in leiomyoma cells was higher than
that in the normal myometrial cells and could be
down-regulated by progesterone. Activity of IL-1b
and TNF-a is particularly important since, on the one
hand, they may directly affect the level of inducible
cyclooxygenase [16,35] and, on the other, they may
indirectly, through TRAF proteins, stimulate activa-
tion of the NF-kB transcription factor [21]. We found
that the expression profile of COX-2 was similar to the
one of TNF-a. Higher imunnoreactivity of COX-2 was
observed in myoma tissue than the control myometri-
Figure 5. iNOS presence in uteri from reproductive (A–C) and perimenopausal age women (D–F). A and D — myome-
trium of control groups, B and E — small myomas, C and F — large myomas. iNOS was detected by IHC as described in
Methods. 200 ×
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um. The overexpression of this enzyme may be relat-
ed to its function in the process of tumorigenesis. It
was found that COX-2 prevented apoptosis and was
associated with inflammation, cell growth and differ-
entiation [5]. Prostaglandins produced via COX-2
activation, including prostaglandin E2 (PGE2), are
believed to be the major contributors to cell prolifer-
ation [36], and PGE2 has been regarded as a primary
COX-2 product in smooth muscle cells [37]. Trans-
fection of rat intestinal epithelial cells with COX-2
gene caused inhibition of apoptosis accompanied by
increased spontaneous output of PGE2 and increased
levels of an anti-apoptotic protein Bcl-2 [38]. Further-
more, it was shown that overexpression of COX-2 pro-
moted angiogenesis and tumor growth in endometri-
al carcinoma [39], and that COX-2 inhibitor in hu-
man prostate cancer cells inhibited their growth [40].
The probability of participation of COX-2 in the pro-
cess of cell growth is supported by the fact that this
enzyme is inducible by growth factors and mitogens
[41]. Similarly to results of our investigations, up-reg-
ulation of COX-2 expression was observed e.g. in car-
cinomas of the lung, colon and breast [3], however, in
uterine leiomyomas, Erol et al. [42] reported oppo-
site observations.
IL-1b and TNF-a are the most prominent cytok-
ines involved in iNOS stimulation. iNOS is one of
three key enzymes generating nitric oxide (NO) which
plays an important role in numerous physiological and
pathophysiological conditions. It is well known that
NO affects the expression of VEGF, angiogenesis,
apoptosis, and prostaglandin production. The role of
iNOS during tumor development is highly complex
and presumably depends on the local concentration
of iNOS within the tumor microenvironment [43]. To
our best knowledge, our study is the first report on
the localization and the immunoreactivity of iNOS in
human uterine myomas. We found significantly higher
immunoreactivity of iNOS in myoma tissue than in
the control myometrium, which suggests an involve-
ment of this enzyme in the pathogenesis of benign
tumors. It seems to be consistent with other investi-
gations that which reported that iNOS expression
correlated with progression of human astrocytoma
[44], human melanoma [45] and prostate cancer [46].
Expression of many cytokines and enzymes, such
as TNF-a, COX-2 and iNOS, which may control cell
proliferation, cell survival or tumor development, was
found to be regulated by a transcription factor-NF-kB
[47, 48]. On the other hand NF-kB activity may be
reciprocally regulated by the cytokines TNF-a or IL-1.
They lead to the phosphorylation and degradation of
IkB, which results in the nuclear transfer of NF-kB.
The classic form of NF-kB is normally retained in
cytoplasm through interactions with inhibitor proteins
IkBa and IkBb [4].  Such a condition probably oc-
curred in our study, since in samples obtained from
control uteri, which contained no myomas, and in
samples with myomas the high immunoreactivity of
NF-kB was restricted exclusively to the cytoplasmic
compartment. No significant differences were ob-
served in the number of stained nuclei between con-
trol groups and myomas groups. It might have been
caused by the fact that there are five members of the
mammalian NF-kB/Rel family and the heterodimer
composed of the p50 and 65 subunits is the classic
form, and we examined only this type of NF-kB. How-
ever, studies of Cogswell et al. [49] indicated that only
p50, p52, and c-Rel subunits were activated in hu-
man breast cancers without a corresponding consis-
tent activation of the p65 subunit. The NF-kB is gen-
erally considered active when it is in the nuclear lo-
calization rather than the cytoplasm. However, the
overall expression level of this protein may also be
related to its activity. Annunziata et al. [50] reported
that an increase in cytoplasmic NF-kB transcription
factor p50 was significantly associated with poorer
patient survival. In myomas, cytoplasmic expression
of NF-kB was highly elevated. Two observations have
drawn our attention. For the first, independently
whether data obtained from small or large myoma
samples were compared, the levels of immunoreac-
tivity in each age group of women were practically
the same. However, samples obtained from women
in reproductive age manifested higher cytoplasmic
expression of NF-kB. Differences in the expression
levels of the examined factors in tissues of women of
different age may be dependent on the hormonal sta-
tus. Our studies, for the first time, indicated the lo-
calization and expression level of NF-kB in uterine
myomas.
In conclusion, higher expression of the examined
factors in uterine myomas in comparison to the con-
trol myometrium suggests involvement of these agents
in the pathogenesis of uterine myomas.
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